About Halo
Halo Pharmaceutical, headquartered in Whippany, New Jersey contract manufactures product for several clients and is a full service FDA, (both CBER and CDER) and DEA (C2-C5) facility. The manufacturing capabilities cover all aspects of commercial production of small molecule and biological drugs, specializing in solid dosage form manufacturing and finished goods packaging.
Halo Pharmaceutical also offers a wide range of analytical development services with expertise in the areas of product and process development, production scale-up and validation, technology transfer and dedicated laboratories and pilot facilities can assist at all stages of development from pre-clinical to phase III.
Halo excels in providing a personalized service and to meeting customer expectations as we partner in the development and manufacture of solids, liquids, suppositories and sterile ointments in a compliant and timely manner.
Halo Completes $14.6 Million in Financing..
Halo Pharmaceutical, this week announced that it has completed $14.6 million in financing from The Provident Bank to expand its operations.
Halo Welcomes Dr. George Bobotas as its Chief Scientific Officer.
As part of a Research and Development partnership between Halo Pharmaceutical and DeMelleBioPharma, LLC, Dr. George Bobotas joins Halo Pharmaceutical as Chief Scientific Officer.
Halo Launched in Canada
Halo has announced today that it is establishing a Canadian subsidiary to be called Halo Pharmaceutical Marketing (Canada) Ltd.
Allen Rosenston appointed VP Business Development.
Adding to its strong executive team, Halo announced the addition of Allen M. Rosenston, a thirty-five year pharmaceutical industry veteran, as Halo's new Vice President of Business Development.
Halo Pharmaceutical, Inc. Acquires Whippany Manufacturing Facility from Abbott.
Halo completes its acquisition of the Whippany-NJ Manufacturing and Research facility from Abbott.
Drug Enforcement Administration - Manufacturer of Controlled Substances; Notice of Registration
DEA has determined that the registration of Halo Pharmaceutical Inc. to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time.
Manufacturing
FDA (CBER/CDER} andDEA (C2-C5) compliant.
Development
We offer our customers a fully integrated and seamless approach to pharmaceutical dosage form development.